Product Description
FL-302 is a tetravalent bispecific antibody in preclinical development targeting both Claudin18.2 and CD137 (4-1BB). FL-302 enhances the activation and function of T cells through the CD137 agonism specifically in the region of CLDN18.2+ tumor cells. This presents an opportunity to improve on the efficacy and safety of early Claudin18.2 and CD137 antibodies when used alone or in combination with other immunotherapies. (Sourced from: https://www.leaptx.com/programs/fl-302/)
Mechanisms of Action: CLDN18.2 Inhibitor,4-1BB Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Leap Therapeutics
Company Location: CAMBRIDGE MA 02142
Company CEO: Douglas E. Onsi
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|